<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737605</url>
  </required_header>
  <id_info>
    <org_study_id>CR106218</org_study_id>
    <secondary_id>2014-004457-14</secondary_id>
    <secondary_id>ESKETINTRD1013</secondary_id>
    <nct_id>NCT02737605</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blind (Periods 1 to 3), Placebo- and Positive-Controlled, Single Dose, 4-Period, Crossover Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the effects of esketamine on QT/QTc intervals and&#xD;
      electrocardiogram (ECG) morphology at therapeutic exposures of esketamine and noresketamine&#xD;
      (intranasal administration) and supratherapeutic exposures of esketamine (intravenous&#xD;
      administration) in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study medication assigned to participants by chance), placebo- and&#xD;
      positive-controlled, double-blind (Periods 1 to 3), and open-label (Period 4), single-dose,&#xD;
      crossover study in up to 60 healthy adults. The study has a Screening Phase and a Treatment&#xD;
      Phase. Participants will be randomly assigned to 1 of 6 treatment sequence groups and will&#xD;
      receive the 4 treatments (1 treatment per period); Treatment A (intravenous placebo,&#xD;
      Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet), Treatment B&#xD;
      (intravenous placebo, 84 milligram (mg) of intranasal esketamine as 4 devices, each with 28&#xD;
      mg esketamine and Oral placebo tablet matched to the moxifloxacin tablet), Treatment C&#xD;
      (intravenous placebo, Intranasal placebo and 400 mg oral moxifloxacin tablet) and Treatment D&#xD;
      (0.8 milligram per kilogram of intravenous esketamine, Intranasal placebo and Oral placebo&#xD;
      tablet matched to the moxifloxacin tablet ). The first 3 periods will be double-blinded and&#xD;
      the fourth period will be open-label. Periods 1, 2, 3, and 4 will be separated by 5 to 7&#xD;
      days. Primarily the effects of esketamine on QT/QTc intervals and electrocardiogram (ECG)&#xD;
      morphology will be evaluated. Safety of the participants will be monitored throughout the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Actual">February 23, 2017</completion_date>
  <primary_completion_date type="Actual">February 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in QTc Interval</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>The QT interval corrected for heart rate (QTc interval) using Fridericia, Bazett and study-specific power correction methods, will be measured by electrocardiograms (ECG).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Maximum Change From Baseline in Electrocardiogram (ECG) Morphology</measure>
    <time_frame>Up to Day 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Predose, 0.25, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 30 hours post-dose on Day 1</time_frame>
    <description>Cmax is defined as maximum observed analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Predose, 0.25, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 30 hours post-dose on Day 1</time_frame>
    <description>Tmax is defined as actual sampling time to reach maximum observed analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to 12 Hours (AUC [0-12])</measure>
    <time_frame>Predose, 0.25, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 30 hours post-dose on Day 1</time_frame>
    <description>The AUC (0-12) is the area under the plasma concentration time curve from time 0 to 12 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUClast)</measure>
    <time_frame>Predose, 0.25, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 30 hours post-dose on Day 1</time_frame>
    <description>The AUClast is area under the plasma concentration time curve from time zero to the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time (AUC [0-infinity])</measure>
    <time_frame>Predose, 0.25, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 30 hours post-dose on Day 1</time_frame>
    <description>The AUC (0-infinity) is area under the plasma concentration time curve from time zero to infinite time, calculated as the sum of Area under Curve (AUC) last and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life Period (T1/2)</measure>
    <time_frame>Predose, 0.25, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 30 hours post-dose on Day 1</time_frame>
    <description>T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda[z]) of the semi logarithmic drug concentrationtime curve, and is calculated as 0.693/lambda(z).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Screening to follow-up visit (within 10 plus or minus 2 days after last dose administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart rate</measure>
    <time_frame>Up to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QRS Interval</measure>
    <time_frame>Up to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PR Interval</measure>
    <time_frame>Up to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in RR Interval</measure>
    <time_frame>Up to Day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A (intravenous placebo, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 1, Treatment B (intravenous placebo, 84 milligram (mg) of intranasal esketamine and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 2, Treatment C (intravenous placebo, Intranasal placebo and 400 mg oral moxifloxacin tablet) on Day 1 of period 3, Treatment D (0.8 milligram per kilogram of intravenous esketamine, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet ) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Esketamine</intervention_name>
    <description>Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Esketamine</intervention_name>
    <description>Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Participants will receive 400 mg Moxifloxacin orally.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>Participants will receive matching placebo orally.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Placebo</intervention_name>
    <description>Participants will receive placebo 40 minutes, intravenous infusion.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Placebo</intervention_name>
    <description>Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed an informed consent document indicating they understand the purpose of and&#xD;
             procedures required for the study and are willing to participate in the study&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30 kilogram (kg)/meter square ([m]^2)&#xD;
             (inclusive), and body weight not less than 50 kilogram (kg)&#xD;
&#xD;
          -  Women using oral contraceptives must agree to use an additional birth control method&#xD;
             during the study and for 1 month after receiving the last dose of study drug or until&#xD;
             after the next menstrual period&#xD;
&#xD;
          -  A woman of child-bearing potential, must have a negative serum beta-human chorionic&#xD;
             gonadotropin (hCG) pregnancy test at Screening and a negative urine pregnancy test on&#xD;
             Day -1 of the first treatment period&#xD;
&#xD;
          -  A man, must agree to use an adequate contraception method as deemed appropriate by the&#xD;
             investigator (example, vasectomy, double-barrier, partner using effective&#xD;
             contraception) and to not donate sperm during the study and for 3 months after&#xD;
             receiving the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a current diagnosis of psychotic disorder or major depressive disorder&#xD;
             (MDD) with psychosis, bipolar or related disorders, intellectual disability,&#xD;
             borderline personality disorder, or antisocial personality disorder&#xD;
&#xD;
          -  Clinically significant medical illness including (but not limited to) cardiac&#xD;
             arrhythmias or other cardiac disease, hematologic disease, lipid abnormalities,&#xD;
             significant pulmonary disease, including bronchospastic respiratory disease, diabetes&#xD;
             mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric&#xD;
             disease, infection, gastrointestinal disease, hypertension, vascular disorders, sleep&#xD;
             apnea, myasthenia gravis, or any other illness that the investigator considers should&#xD;
             exclude the participant or that could interfere with the interpretation of the study&#xD;
             results&#xD;
&#xD;
          -  History of additional risk factors for torsade de pointes or the presence of a family&#xD;
             history of Short QT Syndrome, Long QT Syndrome, sudden unexplained death at a young&#xD;
             age (less than/equal to 40 years), drowning or sudden infant death syndrome in a first&#xD;
             degree relative (that is, biological parent, sibling, or child)&#xD;
&#xD;
          -  Clinically significant abnormal values for hematology, clinical chemistry or&#xD;
             urinalysis at Screening or at admission to the study center for the first treatment&#xD;
             period as deemed appropriate by the investigator. Electrolytes (potassium, magnesium,&#xD;
             calcium) should be within the reference range of the laboratory&#xD;
&#xD;
          -  Clinically significant abnormal physical examination, vital signs, or 12 lead&#xD;
             electrocardiogram (ECG) at Screening or at admission to the study center for the first&#xD;
             treatment period as deemed appropriate by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esketamine</keyword>
  <keyword>Healthy</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Electrocardiogram</keyword>
  <keyword>Repolarization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

